Loading clinical trials...
Loading clinical trials...
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Conditions
Interventions
IMC-C103C
Atezolizumab
+1 more
Locations
19
United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
University of California Davis Comprehenvise Cancer Center
Sacramento, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Oklahoma University Medical Center
Oklahoma City, Oklahoma, United States
Start Date
May 17, 2019
Primary Completion Date
September 25, 2023
Completion Date
September 25, 2023
Last Updated
October 18, 2024
Lead Sponsor
Immunocore Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions